down arrow

Kymera Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5015751044
USD
66.23
1.96 (3.05%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

65.2468.78

52 Week

19.4568.80
Valuation
Technical
Day's Volume

CASH

741.62 k

Shareholding (Mar 2025)

FII

12.52%

Held by 117 FIIs

DII

24.48%

Held by 51 DIIs

Promoter

21.15%

How big is Kymera Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Kymera Therapeutics, Inc. has a market capitalization of $3.02 billion, with net sales of $58.88 million and a net profit of -$240.88 million over the last four quarters. The company reported shareholder's funds of $835.62 million and total assets of $978.03 million as of Dec 24.

Market Cap: As of Jun 18, Kymera Therapeutics, Inc. has a market capitalization of 3,018.29 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Kymera Therapeutics, Inc. reported net sales of 58.88 million and a net profit of -240.88 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 835.62 million and total assets of 978.03 million.

Read More

What does Kymera Therapeutics, Inc. do?

22-Jun-2025

Kymera Therapeutics, Inc. is a small-cap biotechnology company focused on pharmaceuticals, reporting net sales of $22 million and a net loss of $66 million as of March 2025. The company has a market cap of approximately $3.02 billion and does not currently pay dividends.

Overview: <BR>Kymera Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 22 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -66 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,018.29 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.57 <BR>Return on Equity: -30.64% <BR>Price to Book: 3.84<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Should I buy, sell or hold Kymera Therapeutics, Inc.?

22-Jun-2025

Is Kymera Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Kymera Therapeutics, Inc. has a mildly bullish technical trend, supported by positive MACD and Bollinger Bands indicators, daily moving averages, and strong performance relative to the S&P 500.

As of 5 August 2025, the technical trend for Kymera Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also reflect a bullish stance in both time frames. Daily moving averages are bullish, while the KST shows a mildly bearish signal on both weekly and monthly charts. Dow Theory indicates a mildly bullish trend as well. The stock has outperformed the S&P 500 over multiple periods, with a 1-week return of 10.74% compared to 1.05% for the benchmark, and a year-to-date return of 27.17% against 12.22%. Overall, the current technical stance is mildly bullish, supported by strong momentum indicators and positive returns relative to the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate -234.21% of over the last 5 years

 
2

The company has declared negative results for the last 3 consecutive quarters

3

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,093 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.67

stock-summary
Return on Equity

-28.35%

stock-summary
Price to Book

3.18

Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Jun 2025)
Net Profit:
-77 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
52.96%
0%
52.96%
6 Months
51.97%
0%
51.97%
1 Year
41.19%
0%
41.19%
2 Years
218.87%
0%
218.87%
3 Years
115.17%
0%
115.17%
4 Years
24.61%
0%
24.61%
5 Years
30.99%
0%
30.99%

Kymera Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Kymera Therapeutics Hits Day High with 7.95% Surge in Stock Price

Kymera Therapeutics Hits Day High with 7.95% Surge in Stock Price

Kymera Therapeutics, Inc. has seen a significant rise in its stock price, outperforming the S&P 500 over the past week. Despite a strong year-to-date performance, the company faces challenges, including negative operating profit growth and declining net sales, while maintaining a market capitalization of USD 3,093 million.

Read More
Kymera Therapeutics Hits New 52-Week High of $63.29, Up 83.57%

Kymera Therapeutics Hits New 52-Week High of $63.29, Up 83.57%

Kymera Therapeutics, Inc. has achieved a new 52-week high of USD 63.29, reflecting an 83.57% increase over the past year. With a market capitalization of approximately USD 3,093 million, the company operates at a loss and has a unique financial structure, indicated by its negative price-to-earnings ratio.

Read More
Kymera Therapeutics Hits New 52-Week High at $60.00, Up 74.81% Year-to-Date

Kymera Therapeutics Hits New 52-Week High at $60.00, Up 74.81% Year-to-Date

Kymera Therapeutics, Inc. achieved a new 52-week high of USD 60.00 on October 13, 2025, reflecting a significant increase from its low of USD 19.45. With a market capitalization of USD 3,093 million, the company operates in the competitive Pharmaceuticals & Biotechnology sector, despite currently reporting losses.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
36.31%
EBIT Growth (5y)
-234.21%
EBIT to Interest (avg)
-158.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.57
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.94
EV to EBIT
-9.53
EV to EBITDA
-9.81
EV to Capital Employed
7.88
EV to Sales
45.02
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-82.73%
ROE (Latest)
-30.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 62 Schemes (41.83%)

Foreign Institutions

Held by 117 Foreign Institutions (12.52%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -47.96% vs 198.65% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -16.77% vs 7.34% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.50",
          "val2": "22.10",
          "chgp": "-47.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-82.50",
          "val2": "-72.40",
          "chgp": "-13.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-76.60",
          "val2": "-65.60",
          "chgp": "-16.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7,368.20%",
          "val2": "-3,367.70%",
          "chgp": "-400.05%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.08% vs 67.95% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -52.31% vs 5.04% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.10",
          "val2": "78.60",
          "chgp": "-40.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-249.30",
          "val2": "-162.00",
          "chgp": "-53.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-223.90",
          "val2": "-147.00",
          "chgp": "-52.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,453.60%",
          "val2": "-2,106.20%",
          "chgp": "-334.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
11.50
22.10
-47.96%
Operating Profit (PBDIT) excl Other Income
-82.50
-72.40
-13.95%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
-76.60
-65.60
-16.77%
Operating Profit Margin (Excl OI)
-7,368.20%
-3,367.70%
-400.05%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -47.96% vs 198.65% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -16.77% vs 7.34% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
47.10
78.60
-40.08%
Operating Profit (PBDIT) excl Other Income
-249.30
-162.00
-53.89%
Interest
0.20
0.20
Exceptional Items
-4.90
0.00
Consolidate Net Profit
-223.90
-147.00
-52.31%
Operating Profit Margin (Excl OI)
-5,453.60%
-2,106.20%
-334.74%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -40.08% vs 67.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -52.31% vs 5.04% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Kymera Therapeutics, Inc. stock-summary
stock-summary
Kymera Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."